[1] WENG L, ZENG X Y, YIN P, et al. Sepsis-related mortality in China: a descriptive analysis[J]. Intensive Care Med, 2018, 44(7): 1071-1080. [2] 刘杨, 马少林, 王学斌. 血清肝素结合蛋白在脓毒症休克中的预测作用[J]. 中华急诊医学杂志, 2014,23(1):79-83. [3] LIU X W, MA T, LIU W, et al. Sustained increase in angiopoietin-2, heparin-binding protein, and procalcitonin is associated with severe sepsis[J]. J Crit Care, 2018,45:14-19. [4] SHANKAR-HARI M, PHILLIPS G S, LEVY M L, et al. Developing a new definition and assessing new clinical criteria for septic shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)[J]. JAMA, 2016, 315(8):775-787. [5] RHODES A, EVANS L E, ALHAZZANI W, et al. Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016[J]. Intensive Care Med, 2017, 43(3):304-377. [6] ALAM N, OSKAM E, STASSEN P M, et al. Prehospital antibiotics in the ambulance for sepsis: a multicentre, open label, randomised trial[J]. Lancet Respir Med, 2018,6(1):40-50. [7] LIU Y, MA S, WANG X, et al. The role of beta2 integrin associated heparin-binding protein release in ARDS[J]. Life Sci, 2018, 203:92-98. [8] PERSSON B P, HALLDORSDOTTIR H, LINDBOM L, et al. Heparin-binding protein (HBP/CAP37) - a link to endothelin-1 in endotoxemia-induced pulmonary oedema?[J]. Acta Anaesthesiol Scand, 2014, 58(5):549-559. [9] TYDEN J, HERWALD H, HULTIN M, et al. Heparin-binding protein as a biomarker of acute kidney injury in critical illness[J]. Acta Anaesthesiol Scand, 2017,61(7):797-803. [10] LINDER A, CHRISTENSSON B, HERWALD H, et al. Heparin-binding protein: an early marker of circulatory failure in sepsis[J]. Clin Infect Dis, 2009,49(7):1044-1050. [11] 夏勇,郭旭光,廖康.血清肝素结合蛋白对菌血症的诊断价值[J]. 暨南大学学报(自然科学与医学版),2014,35(5):484-489. [12] EMAMI-RAZAVI S H, MOHAMMADI A, ALIBAKHSHI A, et al. Incidence of post-operative sepsis and role of charlson co-morbidity score for predicting postoperative sepsis[J]. Acta Med Iran, 2016, 54(5):318-322. [13] HASHIMOTO H, KITAGAWA K, HOUGAKU H, et al. Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects[J]. Stroke, 2004,35(7):1625-1630. [14] 姚咏明, 栾樱译. 客观评价脓毒症生物标志物的临床意义[J]. 中国危重病急救医学, 2012, 24(9):517-519. [15] 罗雪影, 黄杰清. 联合检测血清 PCT、CRP 及 NEU%早期预测细菌性血流感染的分析[J]. 临床和实验医学杂志, 2015,14(21):1830-1833. [16] 孙萍, 王东强, 刘伟, 等. 脓毒症患者白细胞计数及血清降钙素原和C-反应蛋白的动态变化[J]. 中华危重病急救医学, 2014, 26(7):516-518. [17] ENDO S, AIKAWA N, FUJISHIMA S, et al. Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis: a multicenter prospective study[J]. J Infect Chemother, 2008,14(3):244-249. [18] 叶应妩, 王毓三, 申子瑜. 全国临床检验标准规程[M]. 3版. 南京: 东南大学出版社, 2006: 133-134. [19] MCCABE D J, HARRISON P, MACKIE I J, et al. Increased platelet count and leucocyte-platelet complex formation in acute symptomatic compared with asymptomatic severe carotid stenosis[J]. J Neurol Neurosurg Psychiatry, 2005,76(9):1249-1254. [20] 陈永健, 王毓. 联合肝素结合蛋白和降钙素原诊断脓毒症及分级的临床应用价值[J]. 浙江医学, 2016,38(20):1671-1674. |